Special Issue "Advance in Development of Patient-Centric Dosage Form"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: 10 August 2021.

Special Issue Editors

Dr. Laura Modica de Mohac
E-Mail Website
Guest Editor
Institute of Pharmaceutical Science, King’s College London, London SE19NH , UK
Interests: medicine acceptability; patient-centric formulation; sustained release dosage form; solid dosage form
Dr. Dimitrios A. Lamprou
E-Mail Website
Co-Guest Editor

Special Issue Information

Dear Colleagues,

It is established that the medication acceptability of dosage forms could influence patient compliance and treatment efficacy and safety. Currently, research focuses on developing patient-centric formulations as personalized dosage forms where the product provides the benefits for individual patient needs. According to the World Health Organization (WHO), patient-centric formulations are becoming essential for public health when dealing with long-term diseases treated with multiple drugs. However, data related to the understanding of dosage form-related issues in medication acceptability are lacking. Therefore, the development of advanced technologies has resulted in significant efforts to develop customizable dosage forms.

The focus of this Special Issue of Pharmaceutics will be on assessing and identifying dosage form-related issues in medication acceptability and recent advances in the development of effective strategies to produce patient-centric dosage forms to improve acceptability. This Special Issue will accept both Reviews and Research articles.

Dr. Laura Modica de Mohac
Dr. Dimitrios A. Lamprou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medication acceptability
  • patient-centric dosage forms
  • solid dosage forms
  • assessment
  • advance
  • technology
  • product customization

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Accuracy of Dose Administered to Children Using Off-Labelled or Unlicensed Oral Dosage Forms
Pharmaceutics 2021, 13(7), 1014; https://doi.org/10.3390/pharmaceutics13071014 - 02 Jul 2021
Viewed by 371
Abstract
The pediatric population suffers from a lack of age-appropriate medicines leading to unsafe situations when off-labelled or unlicensed drugs are used. Assessing the best option to administrate medicines when manipulations are required is essential in order to improve child care. This study aimed [...] Read more.
The pediatric population suffers from a lack of age-appropriate medicines leading to unsafe situations when off-labelled or unlicensed drugs are used. Assessing the best option to administrate medicines when manipulations are required is essential in order to improve child care. This study aimed to compare the accuracy of the administered dose provided by three dosage forms and their techniques of administration. Different techniques of administration were assessed, covering three oral dosage forms (commercially available tablets, capsules, oral suspensions) using two APIs not available in a children-adapted dosage form. Techniques of administration were simulated and administered doses were determined using HPLC-UV. Means were compared to the target dose while distributions of doses were compared between each technique. For both APIs, mean administered doses obtained with capsules and tablets were significantly different from the target dose, whereas there was no statistical difference with oral suspensions. Distributions of doses showed significant difference between the three dosage forms. This study demonstrates that manipulations of solid oral dosage forms provide dramatic underdosing leading to unsafe situations. Compounded oral suspension is the best option to avoid underdosing and dose variation. This solution should be prioritized when age-appropriate commercial medicines are not available. Full article
(This article belongs to the Special Issue Advance in Development of Patient-Centric Dosage Form)
Show Figures

Figure 1

Article
Functionality and Acceptance of the EsoCap System—A Novel Film-Based Drug Delivery Technology: Results of an In Vivo Study
Pharmaceutics 2021, 13(6), 828; https://doi.org/10.3390/pharmaceutics13060828 - 02 Jun 2021
Viewed by 734
Abstract
There are no methods for specific local application of active substances to the mucosa of the esophagus to treat eosinophilic esophagitis or other esophageal diseases. This publication describes the principal in vivo functionality and acceptance of a novel modular drug delivery concept, called [...] Read more.
There are no methods for specific local application of active substances to the mucosa of the esophagus to treat eosinophilic esophagitis or other esophageal diseases. This publication describes the principal in vivo functionality and acceptance of a novel modular drug delivery concept, called EsoCap system, by 12 healthy volunteers. For the first time, the EsoCap system enables targeted placement on the esophageal mucosa of a mucoadhesive polymer film. Acceptance was determined by means of a standardized questionnaire after administration and functionality of the device by MRI scans. Two different setups of the EsoCap system were tested: one setup with a density of 0.4 g/cm3 and one with a density of 1.0 g/cm3. Acceptability of the dosage form was also confirmed in addition to functionality, by measuring the applied film length. It was found that acceptance of the variant with the higher density was significantly better. This novel drug delivery technology could enable a targeted, local and long-lasting therapy of the esophagus for the first time, depending on the polymer film used. Full article
(This article belongs to the Special Issue Advance in Development of Patient-Centric Dosage Form)
Show Figures

Graphical abstract

Back to TopTop